3.33
-0.04 (-1.19%)
| Penutupan Terdahulu | 3.37 |
| Buka | 3.28 |
| Jumlah Dagangan | 61,998 |
| Purata Dagangan (3B) | 127,357 |
| Modal Pasaran | 171,043,840 |
| Harga / Jualan (P/S) | 1.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2026 |
| Margin Keuntungan | -41.02% |
| Margin Operasi (TTM) | -18.89% |
| EPS Cair (TTM) | -1.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,407.14% |
| Nisbah Semasa (MRQ) | 2.00 |
| Aliran Tunai Operasi (OCF TTM) | -15.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 10.01 M |
| Pulangan Atas Aset (ROA TTM) | -9.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,552.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | MDxHealth SA | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.22% |
| % Dimiliki oleh Institusi | 43.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mvm Partners, Llc | 31 Dec 2025 | 4,700,457 |
| Panoramic Capital, Llc | 31 Dec 2025 | 238,668 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |